Results of in vivo efficacy testing of PR-104 treatment at 200 mg/kg once a week for 2 weeks in T-ALL and BCP-ALL xenografts
| . | Subtype . | Treatment . | EFS, d . | LGD, d . | Median ORM . | Overall response . |
|---|---|---|---|---|---|---|
| ALL-2 | BCP-ALL | Vehicle | 15.4 | |||
| PR-104 | 31.5 | 16.1 | 8 | CR | ||
| ALL-4 | BCP-ALL | Vehicle | 5.3 | |||
| PR-104 | 27 | 21.7 | 8 | CR | ||
| ALL-19 | BCP-ALL | Vehicle | 7.9 | |||
| PR-104 | 18.2 | 10.3 | 2 | PD2 | ||
| ALL-8 | T-ALL | Vehicle | 2.5 | |||
| PR-104 | 56.8 | 54.3 | 10 | MCR | ||
| ALL-27 | T-ALL | Vehicle | 10.3 | |||
| PR-104 | 69.5 | 59.2 | 10 | MCR | ||
| ALL-29 | T-ALL | Vehicle | 7.0 | |||
| PR-104 | 51.2 | 44.2 | 8 | CR | ||
| ALL-31 | T-ALL | Vehicle | 7.0 | |||
| PR-104 | 51.4 | 44.4 | 8 | CR |
| . | Subtype . | Treatment . | EFS, d . | LGD, d . | Median ORM . | Overall response . |
|---|---|---|---|---|---|---|
| ALL-2 | BCP-ALL | Vehicle | 15.4 | |||
| PR-104 | 31.5 | 16.1 | 8 | CR | ||
| ALL-4 | BCP-ALL | Vehicle | 5.3 | |||
| PR-104 | 27 | 21.7 | 8 | CR | ||
| ALL-19 | BCP-ALL | Vehicle | 7.9 | |||
| PR-104 | 18.2 | 10.3 | 2 | PD2 | ||
| ALL-8 | T-ALL | Vehicle | 2.5 | |||
| PR-104 | 56.8 | 54.3 | 10 | MCR | ||
| ALL-27 | T-ALL | Vehicle | 10.3 | |||
| PR-104 | 69.5 | 59.2 | 10 | MCR | ||
| ALL-29 | T-ALL | Vehicle | 7.0 | |||
| PR-104 | 51.2 | 44.2 | 8 | CR | ||
| ALL-31 | T-ALL | Vehicle | 7.0 | |||
| PR-104 | 51.4 | 44.4 | 8 | CR |
P < 0.001 for the LGD of all xenografts treated with PR-104 compared with vehicle.
CR, complete response; EFS, event-free survival; MCR, maintained complete response; PD2, progressive disease 2.